Novartis's Kymriah Flunks In Late-Stage NHL Study

by Vandana Singh, Benzinga Editor
August 24, 2021 7:50 AM | 29 seconds read |
  • Novartis AG's NVS Kymriah (tisagenlecleucel) CAR-T therapy failed to meet its primary endpoint of event-free survival in a Phase 3 study in aggressive B-cell non-Hodgkin lymphoma (NHL).
  • The BELINDA study included patients after relapse or lack of response to first-line treatment.
  • The safety profile was consistent with the established safety profile of Kymriah.
  • Novartis will complete a full evaluation of the BELINDA study data.
  • Price Action: NVS shares are down 1.05% at $92.77 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareGeneralBriefsNon Hodgkin LymphomaPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!